Your browser doesn't support javascript.
loading
Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites.
Tokarew, Jacqueline M; El-Kodsi, Daniel N; Lengacher, Nathalie A; Fehr, Travis K; Nguyen, Angela P; Shutinoski, Bojan; O'Nuallain, Brian; Jin, Ming; Khan, Jasmine M; Ng, Andy C H; Li, Juan; Jiang, Qiubo; Zhang, Mei; Wang, Liqun; Sengupta, Rajib; Barber, Kathryn R; Tran, An; Im, Doo Soon; Callaghan, Steve; Park, David S; Zandee, Stephanie; Dong, Xiajun; Scherzer, Clemens R; Prat, Alexandre; Tsai, Eve C; Takanashi, Masashi; Hattori, Nobutaka; Chan, Jennifer A; Zecca, Luigi; West, Andrew B; Holmgren, Arne; Puente, Lawrence; Shaw, Gary S; Toth, Gergely; Woulfe, John M; Taylor, Peggy; Tomlinson, Julianna J; Schlossmacher, Michael G.
Afiliação
  • Tokarew JM; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • El-Kodsi DN; Graduate Program in Cellular and Molecular Medicine (Neuroscience), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Lengacher NA; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Fehr TK; Graduate Program in Cellular and Molecular Medicine (Neuroscience), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Nguyen AP; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Shutinoski B; Graduate Program in Cellular and Molecular Medicine (Neuroscience), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • O'Nuallain B; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Jin M; Graduate Program in Cellular and Molecular Medicine (Neuroscience), Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Khan JM; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Ng ACH; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Li J; BioLegend Inc., Dedham, MA, USA.
  • Jiang Q; BioLegend Inc., Dedham, MA, USA.
  • Zhang M; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Wang L; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Sengupta R; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Barber KR; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Tran A; Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
  • Im DS; BioLegend Inc., Dedham, MA, USA.
  • Callaghan S; Department of Biochemistry, Karolinska Institute, Stockholm, Sweden.
  • Park DS; Amity Institute of Biotechnology, Amity University, Kolkata, West Bengal, 700135, India.
  • Zandee S; Department of Biochemistry, University of Western Ontario, London, ON, Canada.
  • Dong X; Department of Biochemistry, University of Western Ontario, London, ON, Canada.
  • Scherzer CR; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Prat A; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Tsai EC; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Takanashi M; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Hattori N; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Chan JA; Department of Neuroscience, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
  • Zecca L; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • West AB; Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.
  • Holmgren A; Department of Neuroscience, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
  • Puente L; Program in Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Shaw GS; Division of Neurosurgery, Department of Surgery, The Ottawa Hospital, Ottawa, ON, Canada.
  • Toth G; Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
  • Woulfe JM; Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
  • Taylor P; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Tomlinson JJ; Institute of Biomedical Technologies, Italian National Research Council, Segrate, Milan, Italy.
  • Schlossmacher MG; Department of Neurobiology, Duke University, Durham, NC, USA.
Acta Neuropathol ; 141(5): 725-754, 2021 05.
Article em En | MEDLINE | ID: mdl-33694021
ABSTRACT
The mechanisms by which parkin protects the adult human brain from Parkinson disease remain incompletely understood. We hypothesized that parkin cysteines participate in redox reactions and that these are reflected in its posttranslational modifications. We found that in post mortem human brain, including in the Substantia nigra, parkin is largely insoluble after age 40 years; this transition is linked to its oxidation, such as at residues Cys95 and Cys253. In mice, oxidative stress induces posttranslational modifications of parkin cysteines that lower its solubility in vivo. Similarly, oxidation of recombinant parkin by hydrogen peroxide (H2O2) promotes its insolubility and aggregate formation, and in exchange leads to the reduction of H2O2. This thiol-based redox activity is diminished by parkin point mutants, e.g., p.C431F and p.G328E. In prkn-null mice, H2O2 levels are increased under oxidative stress conditions, such as acutely by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxin exposure or chronically due to a second, genetic hit; H2O2 levels are also significantly increased in parkin-deficient human brain. In dopamine toxicity studies, wild-type parkin, but not disease-linked mutants, protects human dopaminergic cells, in part through lowering H2O2. Parkin also neutralizes reactive, electrophilic dopamine metabolites via adduct formation, which occurs foremost at the primate-specific residue Cys95. Further, wild-type but not p.C95A-mutant parkin augments melanin formation in vitro. By probing sections of adult, human midbrain from control individuals with epitope-mapped, monoclonal antibodies, we found specific and robust parkin reactivity that co-localizes with neuromelanin pigment, frequently within LAMP-3/CD63+ lysosomes. We conclude that oxidative modifications of parkin cysteines are associated with protective outcomes, which include the reduction of H2O2, conjugation of reactive dopamine metabolites, sequestration of radicals within insoluble aggregates, and increased melanin formation. The loss of these complementary redox effects may augment oxidative stress during ageing in dopamine-producing cells of mutant PRKN allele carriers, thereby enhancing the risk of Parkinson's-linked neurodegeneration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Envelhecimento / Mesencéfalo / Dopamina / Ubiquitina-Proteína Ligases / Degeneração Neural Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Envelhecimento / Mesencéfalo / Dopamina / Ubiquitina-Proteína Ligases / Degeneração Neural Idioma: En Ano de publicação: 2021 Tipo de documento: Article